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Introduction {#sec006}
============

Ischemic heart disease is one of the leading cause of death worldwide, particularly in older people. \[[@pone.0233272.ref001]\] Patients with ischemic heart disease may present with chronic stable angina or acute coronary syndromes. \[[@pone.0233272.ref002]\] Acute coronary syndromes (ACS) include ST-segment elevation myocardial infarction (STEMI) and non-ST elevation ACS, which consists of non-ST elevation myocardial infarction (NSTEMI) and unstable angina. \[[@pone.0233272.ref002]\] The incidence of non-ST elevation ACS is increasing due to the successful application of preventive therapies such as aspirin, statins, smoking cessation, and due to the ageing population. \[[@pone.0233272.ref003]\] In the Global Registry of Acute Coronary Events conducted in 24165 with ACS patients from 102 hospitals in 14 countries, the incidence of NSTEMI increased with advanced age (41% in patients aged ≥85 years compared to 30% in those under 65 years old). \[[@pone.0233272.ref004]\]

In patients with non-ST elevation ACS, early invasive treatment including percutaneous coronary intervention (PCI) in the absence of contraindication is recommended for patients with high risk. \[[@pone.0233272.ref002]\] According to the 2018 ESC/EACTS Guidelines on myocardial revascularization, the decision-making process of PCI for non-ST elevation ACS depends on many factors, including clinical presentation, comorbidities, risk stratification, and other features such as estimated life expectancy, the functional and anatomical severity of the coronary arteries. \[[@pone.0233272.ref005]\] However, there is limited evidence on the treatment of non-ST elevation ACS in the very elderly patients. Patients aged 75 or older just accounted for under 10% of all patients enrolled in trials, and those aged 80 or older were usually excluded from clinical trials. \[[@pone.0233272.ref006]\] Reports of poor outcomes in the elderly from some studies have raised concern about the risk versus benefit of PCI in the treatment of ACS in this population. \[[@pone.0233272.ref003]\]

The world's population is rapidly aging. By 2050 one in five people will be over 60 years old, and the number of people aged over 80 is projected to triple from 143 million in 2019 to 426 million in 2050. \[[@pone.0233272.ref007]\] Over the past decades, the global burden of cardiovascular disease has shifted towards low- and middle-income countries. \[[@pone.0233272.ref001]\] Vietnam is a lower middle-income country in Southeast Asia with rapid urbanization and aging population. In Vietnam, the percentage of older people is significantly increasing, with an estimate of 26.1% people aged 60 plus and 4.2% people aged 80 or older in 2049. \[[@pone.0233272.ref008]\] Previous studies showed that cardiovascular disease is the leading cause of death in Vietnam. \[[@pone.0233272.ref009]--[@pone.0233272.ref012]\] The prevalence of risk factors for ischemic heart disease such as obesity, diabetes, low physical activity, high consumption of alcohol are increasing in Vietnamese people. \[[@pone.0233272.ref013]\] However, there is limited evidence on the management of ACS in the very older patients in this population.

Therefore, this study aims to describe the clinical characteristics of the very elderly patients with non-ST elevation ACS in Vietnam, and to examine the effect of percutaneous coronary intervention on adverse outcomes during 3 months follow up.

Methods {#sec007}
=======

Participants {#sec008}
------------

A prospective, observational cohort study was conducted in patients admitted with ACS to Thong Nhat Hospital in Ho Chi Minh City (Interventional Cardiology Department) and Cho Ray Hospital (Cardiology Department) from 12/2018 to 06/2019. These are the two large tertiary hospitals in Ho Chi Minh City, Vietnam. Consecutive patients were recruited during the study period.

Patients aged ≥80 and were diagnosed with non-ST elevation ACS on admission were invited to participate in this study. We excluded patients who were having: (1) severe illness (dying or receiving intensive care), (2) blind or deaf, (3) severe dementia or delirium, and (4) were unable to speak or understand Vietnamese language.

The study was approved by the ethics committees of the University of Medicine and Pharmacy in Ho Chi Minh City (Reference Number 454/DHYD-HDDD). Written informed consent was obtained from all participants.

Data collection {#sec009}
---------------

Data were collected from patient interviews and from medical records using a predefined data collection form. Information obtained from medical records were: demographic characteristics, height, weight, medical history, comorbidities, admission diagnosis, GRACE score \[[@pone.0233272.ref014]\], coronary angiography and PCI during hospitalization, length of stays, cardiovascular medications prescribed at admission and at discharge, and adverse events during hospitalization (all-cause mortality, recurrent myocardial infarction, stroke, major bleeding, heart failure).

All participants were followed up for 3 months after discharged. Phone calls were conducted to the phone numbers provided by participants or their family to obtain information about adverse events during the 3 months, including readmission, bleeding events, and mortality.

The study major outcomes were: (1) the composite of all-cause mortality, recurrent myocardial infarction and stroke during 3 months since recruited, and (2) re-admission due to cardiovascular causes during 3 months since recruited.

Sample size considerations: We estimated our study sample size based on the result of a study conducted in a cohort of elderly patients with ACS in Sweden. \[[@pone.0233272.ref015]\] In that study in 491 patients (mean age 83), the mortality rate after 1 year was 13% in the PCI group and 39.3% in the non-PCI group. Power analysis indicated that at least 43 participants would be needed in each group to detect the difference in mortality rate (at the power of 80% and p = 0.05).

Statistical analysis {#sec010}
--------------------

Analysis of the study data was performed with SPSS for Windows 24.0. Continuous variables are presented as mean ± standard deviation, and categorical variables as frequency and percentage. Comparisons between the two groups (PCI and non-PCI) were assessed using Chi-square tests for categorical variables and Student's t-tests or Mann-Whitney tests for continuous variables. Two-tailed P values \< 0.05 were considered statistically significant.

To compare the time to the study major outcomes in participants with and without PCI, the Kaplan--Meier estimator was applied to compute survival curves over the 3-month follow-up period and differences between the two groups assessed using log rank tests.

Cox proportional-hazards regressions were conducted to examine the impact of PCI on the study major outcomes, with results presented as hazard ratios (HR) and 95% confidence intervals (CIs). All variables were examined for interaction and multicollinearity.

Results {#sec011}
=======

A total of 120 participants were recruited, mean age 84.8 ± 3.8, 50% were female, 72.5% had two or more chronic diseases. Of these, 42 participants (35.0%) underwent angiography and percutaneous coronary intervention. Overall, participants who received PCI had higher prevalence of hypertension, lower prevalence of heart failure history, lower GRACE score and lower serum creatinine level. There was no significant difference in age, sex, and the presence of multimorbidity between the two groups (**[Table 1](#pone.0233272.t001){ref-type="table"}**).

10.1371/journal.pone.0233272.t001

###### Baseline characteristics of participants.

![](pone.0233272.t001){#pone.0233272.t001g}

                                         All (N = 120)   Participants who did not receive PCI (N = 78)   Participants who received PCI (N = 42)   P
  -------------------------------------- --------------- ----------------------------------------------- ---------------------------------------- -------
  Age                                    84.8 ± 3.8      85.2 ± 4.3                                      84.1 ± 2.6                               0.152
  Female                                 60 (50.0)       43 (55.1)                                       17 (40.5)                                0.126
  Smoking                                45 (37.5)       27 (34.6)                                       18 (42.9)                                0.374
  Multimorbidity (≥2 chronic diseases)   87 (72.5)       57 (73.1)                                       30 (71.4)                                0.847
  Hypertension                           108 (90.0)      67 (85.9)                                       41 (97.6)                                0.041
  Diabetes                               27 (22.5)       18 (23.1)                                       9 (21.4)                                 0.837
  Heart failure                          47 (39.2)       38 (48.7)                                       9 (21.4)                                 0.003
  Stroke                                 4 (3.3)         3 (3.9)                                         1 (2.4)                                  0.670
  Chronic kidney disease                 24 (20.0)       19 (24.4)                                       5 (11.9)                                 0.104
  Previous MI                            20 (16.7)       12 (15.4)                                       8 (19.1)                                 0.608
  Previous PCI                           16 (13.3)       9 (11.5)                                        7 (16.7)                                 0.431
  Previous CABG                          1 (0.8)         0 (0)                                           1 (2.4)                                  0.171
  GRACE score                            162.8 ± 18.6    165.6 ± 20.7                                    157.6 ± 12.2                             0.023
  Blood tests:                                                                                                                                    
  Creatinin (mg/dl)                      1.2 ± 0.4       1.2 ± 0.5                                       1.1 ± 0.3                                0.040
  GFR (ml/m/1.73m^2^)                    59.6 ± 18.8     56.5 ± 19.6                                     65.3 ± 16.1                              0.014

Continuous data are presented as mean ± standard deviation; categorical data are shown as n (%). MI, myocardial infarction. PCI, percutaneous coronary intervention. CABG, coronary artery bypass grafting. GFR, glomerular filtration rate.

The characteristics of coronary lesions and revascularization were described in **[Table 2](#pone.0233272.t002){ref-type="table"}**. Most of the patients had multiple vessel disease (45.2% had 2 vessel disease, 33.3% had 3 vessel disease). Left anterior descending artery (LAD) stenosis was the most common (95.2%), followed by right coronary artery (RCA) (69.0%), and left circumflex artery (LCx) (47.6%). Left main stenosis was present in 28.6% of the participants.

10.1371/journal.pone.0233272.t002

###### Coronary lesions and myocardial revascularisation in participants received angiography and PCI (N = 42).
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                                        N = 42
  ------------------------------------- ------------
  Total number of vessel disease        2.1 ± 0.7
  No vessel disease                     0 (0)
  1 vessel disease                      9 (21.4)
  2 vessel disease                      19 (45.2)
  3 vessel disease                      14 (33.3)
  Left main stenosis                    12 (28.6)
  LAD stenosis                          40 (95.2)
  RCA stenosis                          29 (69.0)
  LCx stenosis                          20 (47.6)
  PCI                                   42 (100.0)
  PCI within 24 hours since admission   10 (23.8)
  PCI at 24--72 hours since admission   18 (42.9)
  PCI after 72 hours since admission    14 (33.3)

Continuous data are presented as mean ± standard deviation; categorical data are shown as n (%). PCI, percutaneous coronary intervention. LAD, left anterior descending artery. RCA, right coronary artery. LCx, left circumflex artery.

**[Table 3](#pone.0233272.t003){ref-type="table"}**presents the use of cardiovascular medication during hospitalization and at discharge. Overall, upon discharge, the prescription of secondary prevention medications was high in patients aged 80 years or older with ACS (aspirin 95.0%, clopidogrel 77.5%, statins 89.2%, angiotensin converting enzyme (ACE) inhibitors/ angiotensin II receptor blockers (ARBs) 80.8%, beta-blockers 69.2%). The prescription of secondary prevention medications was similar in patients with and without PCI, except for statin (97.6% in patients with PCI compared to 84.6% in patients without PCI, p = 0.03).

10.1371/journal.pone.0233272.t003

###### Cardiovascular medication use at admission and at discharge.
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                            All (N = 120)   Participants who did not receive PCI (N = 78)   Participants who received PCI (N = 42)   P
  ------------------------- --------------- ----------------------------------------------- ---------------------------------------- ---------
  At admission:                                                                                                                      
  Enoxaparin                90 (75.0)       67 (85.9)                                       23 (54.76)                               \<0.001
  Aspirin                   120 (100.0)     78 (100.0)                                      42 (100.0)                               N/A
  Clopidogrel               100 (80.3)      70 (89.74)                                      30 (71.43)                               0.01
  Ticagrelor                12 (10.0)       0 (0.0)                                         12 (28.6)                                \<0.001
  Statin                    113 (94.2)      72 (98.3)                                       41 (97.6)                                0.236
  Beta-blockers             65 (54.2)       39 (50.0)                                       26 (61.9)                                0.212
  ACE inhibitors/ARBs       98 (81.7)       60 (76.9)                                       38 (90.5)                                0.067
  Aldosterone antagonists   63 (52.5)       40 (51.28)                                      23 (54.76)                               0.716
  Nitrate                   61 (50.8)       39 (50.0)                                       22 (52.4)                                0.803
  At discharge:                                                                                                                      
  Aspirin                   114 (95.0)      72 (92.3)                                       42 (100.0)                               0.090
  Clopidogrel               93 (77.5)       63 (80.8)                                       30 (71.4)                                0.243
  Ticagrelor                12 (10.0)       0 (0.0)                                         12 (28.6)                                \<0.001
  Statin                    107 (89.2)      66 (84.6)                                       41 (97.6)                                0.032
  Beta-blockers             83 (69.2)       50 (64.1)                                       33 (78.6)                                0.102
  ACE inhibitors/ARBs       97 (80.8)       59 (75.6)                                       38 (90.5)                                0.055
  Aldosterone antagonists   61 (50.8)       38 (48.7)                                       23 (54.8)                                0.528
  Nitrate                   58 (48.3)       36 (46.2)                                       22 (52.4)                                0.515

Continuous data are presented as mean ± standard deviation; categorical data are shown as n (%). PCI, percutaneous coronary intervention. ACE, Angiotensin-converting-enzyme. ARBs, angiotensin II receptor blockers.

Compared to participants who did not receive PCI, participants who received PCI had significantly lower rates of adverse outcomes during hospitalization and during 3 months of follow up. The rate of major bleeding was low during hospitalization (0.83% overall, 0% in the PCI group versus 1.3% in the non-PCI group, p = 0.461) and during 3 months follow up (2.5% overall, 4.8% in the PCI group versus 1.3% in the non-PCI group, p = 0.280). (**[Table 4](#pone.0233272.t004){ref-type="table"}**)

10.1371/journal.pone.0233272.t004

###### Adverse outcomes of the participants during hospitalization and after 3 months of follow up.

![](pone.0233272.t004){#pone.0233272.t004g}

                                             All (N = 120)   Participants who did not receive PCI (N = 78)   Participants who received PCI (N = 42)   P
  ------------------------------------------ --------------- ----------------------------------------------- ---------------------------------------- ---------
  Hospitalisation length (days)              7.1 ± .1.5      7.7 ± 1.3                                       6 ± 1.2                                  \<0.001
  Adverse outcomes during hospitalisation:                                                                                                            
  All-cause mortality                        6 (5.0)         6 (7.7)                                         0 (0)                                    0.064
  Recurrent myocardial infarction            40 (33.3)       34 (43.6)                                       6 (14.3)                                 0.001
  Stroke                                     0 (0.0)         0 (0)                                           0 (0)                                    N/A
  Congestive heart failure                   57 (47.5)       46 (58.9)                                       11 (26.2)                                0.001
  Major bleeding                             1 (0.83)        1 (1.3)                                         0 (0)                                    0.461
  Adverse outcomes after 3 months:                                                                                                                    
  Re-admission                               49 (43.0)       37 (51.4)                                       12 (28.6)                                0.018
  Composite outcomes                         34 (28.3)       29 (37.2)                                       5 (11.9)                                 0.003
  All-cause mortality                        23 (19.2)       20 (25.6)                                       3 (7.1)                                  0.015
  Recurrent myocardial infarction            9 (7.5)         8 (10.3)                                        1 (2.4)                                  0.158
  Stroke                                     2 (1.7)         1 (1.3)                                         1 (2.4)                                  1.000
  Major bleeding                             3 (2.5)         1 (1.3)                                         2 (4.8)                                  0.280

Composite outcomes were defined as the combination of all-cause mortality, recurrent myocardial infarction, stroke. PCI, percutaneous coronary intervention.

The Kaplan-Meier survival function for composite outcome and readmission indicated that at all points in time during the three-month follow-up, participants who received PCI treatment were less likely to have the composite outcome (Log Rank Chi-Square 4.564, 1df, p = 0.033 and Breslow Chi-Square 5.000, 1df, p = 0.025) and less likely to be readmitted to hospitals (Log Rank Chi-Square 5.733, 1df, p = 0.017 and Breslow Chi-Square 6.138, 1df, p = 0.013) compared to those who did not receive PCI (**Figs [1](#pone.0233272.g001){ref-type="fig"} and [2](#pone.0233272.g002){ref-type="fig"}**).

![The Kaplan-Meier survival curves for composite outcome after 3 months in participants with and without PCI.\
PCI, percutaneous coronary intervention.](pone.0233272.g001){#pone.0233272.g001}

![The Kaplan-Meier survival curves for readmission after 3 months in participants with and without PCI.\
PCI, percutaneous coronary intervention.](pone.0233272.g002){#pone.0233272.g002}

On univariate survival analyses, only PCI (unadjusted HR 0.27, 95%CI 0.10--0.70), age (unadjusted HR 1.15, 95%CI 1.05--1.26) and GRACE score (unadjusted HR 1.02, 95%CI 1.00--1.04) were significantly associated with the composite outcome. (**[Table 5](#pone.0233272.t005){ref-type="table"}**) The relationship between PCI and the composite outcome was still significant after adjusted for age and GRACE score in multivariate survival analysis (adjusted HR 0.32, 95%CI 0.12--0.86).

10.1371/journal.pone.0233272.t005

###### Cox proportional hazards model of PCI and other related factors on time to adverse outcomes after 3 months follow up in patients aged ≥80 with ACS.
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  Outcomes                               Unadjusted HR (95%CI) for the composite outcome (N = 120)   P       Unadjusted HR (95%CI) for re-admission (N = 114)   P
  -------------------------------------- ----------------------------------------------------------- ------- -------------------------------------------------- -------
  PCI                                    0.27 (0.10--0.70)                                           0.007   0.26 (0.09--0.75)                                  0.013
  Age                                    1.15 (1.05--1.26)                                           0.002   1.07 (0.96--1.19)                                  0.250
  Female                                 0.92 (0.46--1.82)                                           0.807   0.90 (0.41--1.98)                                  0.797
  GRACE score                            1.02 (1.00--1.04)                                           0.025   1.00 (0.98--1.03)                                  0.730
  Heart failure                          1.63 (0.82--3.23)                                           0.160   1.64 (0.75--3.59)                                  0.218
  Diabetes                               0.46 (0.16--1.31)                                           0.147   0.34 (0.08--1.44)                                  0.143
  Hypertension                           0.54 (0.21--1.39)                                           0.198   0.66 (0.20--2.19)                                  0.494
  Stroke                                 2.05 (0.49--8.57)                                           0.327   3.38 (0.79--14.48)                                 0.101
  History of IHD                         1.30 (0.59--2.88)                                           0.519   2.21 (0.95--5.13)                                  0.064
  Chronic kidney disease                 1.33 (0.60--2.95)                                           0.480   1.22 (0.46--3.26)                                  0.687
  Multimorbidity (≥2 chronic diseases)   0.64 (0.32--1.31)                                           0.222   0.73 (0.32--1.66)                                  0.455

PCI, percutaneous coronary intervention. IHD, ischemic heart disease.

Cox proportional hazards models on PCI and other related factors on time to re-admission show that only PCI was significantly associated with 3-month re-admission (unadjusted HR 0.26, 95%CI 0.09--0.75). Multivariate survival analysis was not applied for 3-month re-admission as there were no other factors that show significant association with this outcome on univariate analysis ([Table 5](#pone.0233272.t005){ref-type="table"}).

Discussion {#sec012}
==========

In this study in patients aged 80 years or older with non-ST elevation ACS, only around one third of the participants received PCI treatment. Overall, the prevalence of multimorbidity and the multiple coronary vessel disease was high in the participants. The prescription of secondary prevention medications at discharge was high in both groups of patients with and without PCI. PCI was significantly associated with reduced adverse outcomes during the 3 months follow up. The rate of major bleeding was low and there was no significant difference between the PCI group and the non-PCI group.

Our findings are compatible with other studies in this topic in the world. Older people with acute coronary syndrome usually have multiple chronic health conditions. \[[@pone.0233272.ref016]\] Previous studies showed that older patients are less likely to receive PCI, and coronary lesions in older people are usually complicated and involved multiple vessels. \[[@pone.0233272.ref003],[@pone.0233272.ref004],[@pone.0233272.ref016]\] In the Global Registry of Acute Coronary Events Study in 35512 patients with non-ST elevation ACS from 113 hospitals from 14 countries in North and South America, Europe, Australia and New Zealand, angiography was performed in 33% of the very elderly (compared to 67% in younger patients). \[[@pone.0233272.ref017]\]

In the past, the rate of complications after PCI in older people was higher compared to younger people, however, in recent years, due to advance in interventional cardiology, the number of older patients with non-ST elevation ACS that received PCI treatment is increasing. \[[@pone.0233272.ref003],[@pone.0233272.ref018]\] Many studies have shown that PCI in older patients is effective in reducing adverse outcomes without increasing bleeding risk. According to the After Eighty Study, a randomized controlled trial in patients aged 80 years or older with non-ST elevation ACS (229 participants in the invasive group and 228 participants in the conservative group), an invasive strategy is superior to a conservative strategy in the reduction of composite events, and there was no difference in the rates of bleeding complications between the two strategies. \[[@pone.0233272.ref019]\] In the Acute Coronary Syndromes Registry study in 1936 patients ≥75 years with NSTEMI (1005 patients underwent coronary angiography and revascularization if indicated, and 931 patients received conservative treatment), in-hospital mortality and the combined outcome of mortality/non-fatal recurrent myocardial infarction were lower in patients receiving invasive management compared with those managed by conservative strategy (6.0% versus 12.5%, p\<0.001 and 9.6% vs 17.3%, p\<0.001, respectively). \[[@pone.0233272.ref020]\] There was also a significant reduction in 1-year mortality in the invasive treatment group compared to the conservative treatment group (OR 0.56, 95% CI 0.38--0.81). \[[@pone.0233272.ref020]\] In the Italian Elderly ACS study in 313 non-ST elevation ACS patients ≥75 years old, there was a significant reduction in the primary outcome (death, myocardial infarction, stroke, and readmission due to cardiovascular causes) in the early aggressive treatment group with elevated troponin on admission compared to the conservative group at 1 year (HR 0.43, 95% CI 0.23--0.80). \[[@pone.0233272.ref021]\] In the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH), clinical data and outcomes of all patients undergoing cardiac catheterization and revascularisation in the province of Alberta, Canada since 1995 were recorded. They found that the absolute risk differences in comparison to medical therapy for PCI and coronary artery bypass grafting (CABG) were greater for patients aged 80 or older compared to younger patients. In 983 patients aged 80 plus, survival was 71.6% for PCI, 77.4% for CABG and 60.3% for medical therapy. \[[@pone.0233272.ref022]\]

In this study in the over 80s with ACS, we also found that the prevalence of prescription of secondary prevention medications was high and similiar between the PCI and non-PCI group (except for statin). This finding is compatible to a previous study conducted in 2013 at other hospitals in Vietnam, in which a high physicians' adherence to prescribing guidelines for ACS was reported. \[[@pone.0233272.ref023]\]

Strength and limitations {#sec013}
------------------------

To our best knowledge, this is the first study describing the clinical characteristics of patients aged 80 years or older with non-ST elevation ACS in Vietnam and investigating the effect of PCI on adverse outcomes in this population. This study was conducted at two large tertiary hospitals in Ho Chi Minh City, Vietnam and contained high quality detailed clinical information. The major limitation of this study is that the follow up time was short. The second limitation is that information on socioeconomics of the participants was not collected. In Vietnam, socioeconomic status may have a significant impact on the rate of PCI treatment in patients with ACS. Thirdly, this study was conducted in elderly patients at only two hospitals, which may not be representative for all older patients with non-ST elevation ACS in Vietnam.

Implications for research and clinical practice {#sec014}
-----------------------------------------------

The clinical evidence for treatment of ACS in the elderly is less robust than in younger patients and in fact, there is no specific guidelines for the management of ACS in general and non-ST elevation ACS in particular in patients aged 80 years or older. In elderly patients, non-ST elevation ACS is more common than STEMI. \[[@pone.0233272.ref024]\] In Vietnam, there has been limited evidence on the epidemiology and treatment of non-ST elevation ACS in patients aged 80 years or older. This study suggests further research on this topic in Vietnam. Most of older people in Vietnam (around 73%) are living in rural areas, where most hospitals do not have interventional facilities. \[[@pone.0233272.ref025]\] Evidence from large international cohort studies showed that the availability of interventional facilities at the admitting hospital is a major predictor of cardiac catheterization and PCI procedure. \[[@pone.0233272.ref026],[@pone.0233272.ref027]\] While the recognition and treatment for STEMI is more straightforward, non-ST ACS may be more likely to be under-evaluated and under-treated, especially in rural settings. The findings from this study also suggest the need to increase awareness about the benefits of PCI for patients aged 80 years or older with non- ST elevation ACS in Vietnam, especially in rural clinical settings, and to develop strategies to ensure that elderly patients with non-ST elevation ACS who are candidates for PCI should be promptly referred to hospitals with interventional facilities.

Conclusion {#sec015}
==========

In this study in patients aged 80 years or older with non-ST elevation ACS in Vietnam, one third of the participants received PCI treatment and we found that PCI was significantly associated with reduced adverse outcomes during the study follow up time. The findings of this study contribute to the evidence of the benefits of PCI treatment in older patients with non-ST elevation ACS. Advanced aged alone should not be a contra-indication for PCI and all patients with non-ST elevation ACS should be evaluated and managed according to the current guidelines.

Supporting information {#sec016}
======================
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Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Interesting paper entitled \"Non-ST elevation acute coronary syndrome in patients aged 80 years or older in

Vietnam: an observational study\" where the authors state that sample size was not calculated as major limitation. This element limits unfortunately any interpretation of the data collected

Reviewer \#2: This paper by Tan Van Nguyen et al. was aimed to assess the impact of PCI in ACS patients aged \> 80ys.

This was a non randomized prospective study enrolling 120 patients, among those 42 participants (35.0%) were treated with invasive strategy. At three months follow up patients who received PCI had significantly lower rates of adverse outcomes.

This study has several limitations:

\- The sample size is quite small to assess hard end points (mortality and cardiovascular events)

\- The authors did not mention the reason why patients were treated with invasive or medical treatment

\- Baseline condition of patient treated with PCI or medical therapy were different, with better status of patient treated with PCI

\- It is already known that older patients with ACS treated with invasive strategy may benefit even more that young patients from guidelines indicated PCI. I believe the authors should focus more on the novelty of implementing a national system for invasive treatment of ACS also in mid- low income countries.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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We would like to thank the reviewers for the time spent reviewing our manuscript and for the useful comments, and to thank the editors for the opportunity to respond.

We feel that the suggestions have strengthened the manuscript and have tried to address as many of the suggestions as possible as detailed below. We would be happy to address any further issues if required.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Interesting paper entitled \"Non-ST elevation acute coronary syndrome in patients aged 80 years or older in Vietnam: an observational study\" where the authors state that sample size was not calculated as major limitation. This element limits unfortunately any interpretation of the data collected

Response: We have added our justification for sample size. Please see lines 105-110:

"Sample size considerations: We estimated our study sample size based on the result of a study conducted in a cohort of elderly patients with ACS in Sweden.14 In that study in 491 patients (mean age 83), the mortality rate after 1 year was 13% in the PCI group and 39.3% in the non-PCI group. Sample size calculations indicated that at least 43 participants would be needed in each group to detect the difference in mortality rate (at the power of 80% and p=0.05)."

Reviewer \#2: This paper by Tan Van Nguyen et al. was aimed to assess the impact of PCI in ACS patients aged \> 80ys.

This was a non randomized prospective study enrolling 120 patients, among those 42 participants (35.0%) were treated with invasive strategy. At three months follow up patients who received PCI had significantly lower rates of adverse outcomes.

This study has several limitations:

\- The sample size is quite small to assess hard end points (mortality and cardiovascular events)

Response: We have added our justification for sample size. Please see lines 105-110.

\- The authors did not mention the reason why patients were treated with invasive or medical treatment.

Response: We have added the information for PCI decision in patients with non-ST elevation ACS as follows: (please see lines 59-63)

"According to the 2018 ESC/EACTS Guidelines on myocardial revascularization, the decision-making process of PCI for non-ST elevation ACS depends on many factors, including clinical presentation, comorbidities, risk stratification, and other features such as estimated life expectancy, the functional and anatomical severity of the coronary arteries"

\- Baseline condition of patient treated with PCI or medical therapy were different, with better status of patient treated with PCI

Response: There was no significant difference in age, sex, and the presence of multimorbidity between patients who did and did not receive PCI. Patients with PCI had higher prevalence of hypertension, lower prevalence of heart failure, lower GRACE score and lower serum creatinine level. As patients treated with PCI had slightly better status, we did examine the influence of these factors in univariate and multivariate survival analysis. (Please see Table 5)

\- It is already known that older patients with ACS treated with invasive strategy may benefit even more that young patients from guidelines indicated PCI. I believe the authors should focus more on the novelty of implementing a national system for invasive treatment of ACS also in mid- low income countries.

Response: Thank you for your suggestion. We have added a section of implications as follows (please see lines 223-239):

"Implications for research and clinical practice

The clinical evidence for treatment of ACS in the elderly is less robust than in younger patients and in fact, there is no specific guidelines for the management of ACS in general and non-ST elevation ACS in particular in patients aged 80 years or older. In elderly patients, non-ST elevation ACS is more common than STEMI.24 In Vietnam, there has been limited evidence on the epidemiology and treatment of non-ST elevation ACS in patients aged 80 years or older. This study suggests further research on this topic in Vietnam. Most of older people in Vietnam (around 73%) are living in rural areas, where most hospitals do not have interventional facilities.25 Evidence from large international cohort studies showed that the availability of interventional facilities at the admitting hospital is a major predictor of cardiac catheterization and PCI procedure. 26,27 While the recognition and treatment for STEMI is more straightforward, non-ST ACS may be more likely to be under-evaluated and under-treated, especially in rural settings. The findings from this study also suggest that there is a need to increase awareness about the benefits of PCI for patients aged 80 years or older with non-ST elevation ACS in Vietnam, especially in rural clinical settings, and to develop strategies to ensure that elderly patients with non-ST elevation ACS who are candidates for PCI should be promptly referred to hospitals with interventional facilities. "

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
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Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. Please ensure that you refer to Figure 2 in your text as, if accepted, production will need this reference to link the reader to the figure.

Response: We have added the reference linked to Figure 2 in the main text (Please see line 148)

2\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <https://protect-au.mimecast.com/s/U67cCwV1vMfP99JvH1Sq19?domain=journals.plos.org>.

Response: We have added the caption (Please see line 260)
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